Skip to main content

Does Medicare Cover GLP-1 Weight Loss Drugs Like Ozempic and Zepbound?

GLP-1 medications, such as Ozempic, Zepbound and Wegovy, have emerged as a significant advancement in the treatment of various conditions, including Type 2 diabetes, heart disease, obstructive sleep apnea, kidney disease and obesity. As demand for these drugs grows, many Medicare beneficiaries are left wondering: Does Medicare cover GLP-1s for weight loss and other chronic conditions?

[READ: The GLP-1 Effect: Beyond Weight Loss and Into Longevity]

What Are GLP-1 Drugs?

Injectable GLP-1 (glucagon-like peptide-1) receptor agonists were first introduced for managing Type 2 diabetes, a condition that affects over a quarter of Medicare beneficiaries, according to the Centers for Medicare and Medicaid Services (CMS). They work by mimicking the naturally occurring hormone GLP-1, which is released by the body when you eat. This hormone helps control blood sugar by enhancing insulin secretion, reducing levels of glucagon (a hormone that raises blood sugar) and slowing gastric emptying.

Scientists have discovered that GLP-1 drugs also produce meaningful weight loss. This is particularly relevant for the Medicare population, as a 2024 Congressional Budget Office (CBO) report found that about two-thirds of beneficiaries were classified as either overweight (35%), defined as a BMI of between 25 and 29.9, or obese (34%), which is a BMI of 30 and above.

“There is a definite correlation between Type 2 diabetes and obesity. In fact, at least 85% of Type 2 diabetes occurs in patients who are overweight or have obesity,” says Dr. Lydia C. Alexander, chief medical officer for Enara Health in San Mateo, California.

Not only do these medications help control Type 2 diabetes and weight loss, but the Food and Drug Administration has also approved certain ones for conditions such as heart disease, obstructive sleep apnea and kidney disease. Researchers are now studying them for a wide array of other diseases, including neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease, addiction and substance use disorders, certain liver diseases, polycystic ovary syndrome and chronic obstructive pulmonary disease.

[SEE: Navigating Insurance Coverage for GLP-1 Medications: A Step-by-Step Guide]

Which GLP-1s Does Medicare Cover?

Federal law currently prevents Medicare from covering weight loss drugs. However, Medicare Part D and Medicare Advantage plans cover certain GLP-1s to treat approved conditions, as determined by the FDA. Medicare Part D will cover GLP-1 medications when they are used to treat Type 2 diabetes, obstructive sleep apnea or people with pre-existing cardiovascular disease who need to lose weight.

For example, Medicare Part D plans may cover Wegovy if it’s prescribed to reduce the risk of cardiovascular death, heart attack or stroke in overweight/obese adults. If covered, Wegovy is usually on a high specialty tier, with costs potentially ranging from $325 to $430 per month depending on the plan.

Before going straight to a GLP-1 medication, however, many plans require a step therapy approach. In this approach, a patient must try one or more lower-cost or preferred medications (called “first-line therapies”) before the plan will cover a more expensive or non-preferred drug.

“A stepped care approach utilizes all the tools available in the treatment of obesity to optimize outcomes in a cost-thoughtful fashion,” Alexander says.

There are several brands of weight loss medications available, so it’s essential to understand the differences between them and what they’re approved to cover.

GLP-1 medications that your Medicare plan might include and what conditions they’re covered for

Commercial Drug Name Chemical Name FDA-Approved Health Conditions
Ozempic Semaglutide Type 2 diabetes; To reduce the risk of major cardiovascular events (heart attack, stroke, death) in adults with Type 2 diabetes and heart disease; To reduce the risk of kidney disease progression, kidney failure, and CV death in adults with Type 2 diabetes and chronic kidney disease.
Wegovy Semaglutide Chronic weight management in adults (obesity or overweight with a comorbidity) and children 12+; To reduce the risk of major cardiovascular events in adults with heart disease and obesity/overweight; Accelerated approval for metabolic dysfunction-associated steatohepatitis (MASH).
Rybelsus Semaglutide Type 2 diabetes; To reduce the risk of major cardiovascular events in high-risk adults with Type 2 diabetes (oral version).
Mounjaro Tirzepatide Type 2 diabetes in adults and pediatric patients aged 10 and older.
Zepbound Tirzepatide Chronic weight management (obesity or overweight with a comorbidity); Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
Victoza Liraglutide Type 2 diabetes; To reduce the risk of major cardiovascular events in adults with Type 2 diabetes and heart disease.
Saxenda Liraglutide Chronic weight management in adults and children aged 12-17 with obesity or overweight.
Trulicity Dulaglutide Type 2 diabetes; To reduce the risk of major cardiovascular events in adults with Type 2 diabetes and heart disease or multiple CV risk factors.

Other weight loss support with Medicare

While Medicare does not cover GLP-1s specifically for weight loss, Medicare does cover some obesity treatments, such as intensive behavioral therapy and bariatric surgery.

The Medicare Part B program offers no-cost obesity screenings and behavioral counseling through its Intensive Behavioral Therapy for Obesity initiative for beneficiaries with a BMI of 30 or higher.

Some Medicare Advantage plans provide enhanced coverage that can support your weight loss efforts, such as gym memberships and subscriptions to fitness programs like SilverSneakers.

[READ: Worst Medicare Advantage Plans: How to Find a Good One]

How Much Do GLP-1s Cost Under Medicare Plans?

The cost of these medications varies with Medicare Part D and Medicare Advantage, depending on several factors, including:

— Your specific Medicare plan

— Whether you have a stand-alone prescription drug plan through Medicare Part D or a Medicare Advantage plan

— Which tier it’s under on your plan’s formulary

— What your out-of-pocket costs may be, such as your deductible, co-pay or coinsurance

Not all plans cover all GLP-1 medications, so it’s essential to check with your plan to determine what’s available to you.

[READ: How Medicare Beneficiaries Can Save Money on Prescription Drugs]

Medicare and Weight Loss Drugs

There’s growing recognition that obesity is a chronic disease with profound health implications. Yet Medicare can’t cover medications solely for weight loss under current law.

“As more super-effective anti-obesity medications are FDA-approved, this will continue to increase the understanding that obesity is a neuroendocrine regulatory dysfunction rather than a failure of willpower to reach a healthy weight,” Alexander observes.

On December 23, 2025, the Centers for Medicaid & Medicare Services announced the The BALANCE Model, which stands for Better Approaches to Lifestyle and Nutrition for Comprehensive Health. This initiative aims to increase coverage to select GLP-1 weight loss medications. The model is a five-year demonstration scheduled to start for Medicaid in May 2026 and for Medicare Part D in January 2027.

According to a press release, CMS will directly negotiate with voluntary eligible GLP-1 manufacturers on behalf of state Medicaid agencies and Medicare Part D plans for lower net prices and standardized coverage terms. Participation will be voluntary for manufacturers, states and plans.

Eligible beneficiaries must meet standardized coverage criteria (which include BMI cutoffs that are narrower than the current FDA guidelines) and must also participate in evidence-based, lifestyle-support offerings. While the FDA defines obesity as anyone with a BMI above 30, the BALANCE demo will only apply to adults with a BMI of 35 and higher to take a GLP-1 drug for solely weight loss. Under BALANCE, those who qualify are expected to pay a $50-$125 a month copay after deductible for GLP-1 medications, depending on the type of Part D Plan they have.

For those with a Medicare Part D plan, a six-month “bridge” program for BALANCE is expected to begin in July 2026. According to CMS, this bridge program will operate outside of Medicare Part D coverage, so Part D Plan sponsors will not carry risk for eligible GLP-1 products under the demonstration.

[READ Can Microdosing Weight Loss Drugs Like Ozempic Help You Lose Weight?]

Ways to Save on Drug Costs

The high price tag of these medications makes them unaffordable for many. If you’re interested in finding out what they may cost you without insurance or want to lower your co-pay, here are a few ways to look for savings:

Contact the drug companies. Sometimes, directly speaking with a representative of the pharmaceutical company can help you determine your options.

Look online. Retail prescription websites, such as GoodRx, SingleCare and WellRx, can help you find the best price by monitoring prices at different pharmacies to guide you to the most affordable option. What you find, however, may still be cost-prohibitive.

Manufacturer coupons and patient assistance programs. Depending on various factors, including the type of insurance you have, you may qualify for a manufacturer coupon. Many drug companies also offer programs to those who may benefit from, but cannot afford, certain medications. Each medication’s website will have further information.

Talk to your doctor. Your doctor may have insight into accessing GLP-1 drugs for less than the list price. For instance, your physician may be able to steer you to a local compounding pharmacy that can offer their own version of the medicine that they make on site. It should be noted that compounded GLP-1s aren’t approved by the Food and Drug Administration, and the FDA has been trying to crack down on patients getting compounded versions of GLP-1s.

Bottom Line

While some GLP-1s are FDA-approved for conditions beyond diabetes and are therefore potentially covered, Medicare does not cover them solely for weight loss. Coverage under Medicare Part D or Medicare Advantage plans depends on the drug’s approved use and your plan’s formulary. Costs vary based on your specific coverage details. Patients can explore savings options that may offer access to more affordable prices.

The expanded Medicare coverage for obesity treatment under the BALANCE model may offer lower GLP-1 pricing, but it’s too soon to say how this benefit will actually play out.

More from U.S. News

Breast Pain? Stop Worrying About Cancer

Factors That Can Weaken Your Immune System

8 Questions to Ask Before a Cosmetic Procedure

Does Medicare Cover GLP-1 Weight Loss Drugs Like Ozempic and Zepbound? originally appeared on usnews.com

US embassies in the Middle East prepare for extended period with reduced staff amid Iran war

(CNN) — The State Department is asking US embassies in the Middle East to create plans to continue operating with a small number of staff on the ground, sources told CNN, as the war with Iran shows no signs of resolution.Additionally, personnel who have been displaced from their posts in the Middle East are increasingly being given the option to curtail their assignments, the sources said.The plans have not been finalized, the sources said, and it is unclear if they will be implemented at all of the embassies that are currently on reduced staffing. Still, the developments underscore that the State Department does not expect to return to normal staffing in the region soon amid the looming threat of a full-scale return to war.A State Department spokesperson told CNN that they “do not discuss internal deliberations or post-specific contingency planning,” but noted that the department “continually reviews the security and staffing posture at every diplomatic mission based on conditions on the ground and adjusts personnel levels as appropriate.”“The safety and security of our personnel and their families remains the Department’s top priority as we continue to assess conditions across the region,” the spokesperson said. “Decisions regarding the status of any post are made based on a range of security and operational factors, in close coordination between posts and Washington.”“Personnel matters, including individual curtailment requests, are handled on a case-by-case basis,” they added.The State Department ordered nonemergency personnel and family members to leave almost every diplomatic post in the region shortly after the war began in late February. That has led to nearly six months of uncertainty about whether the posts would be able to return to normal and all diplomats could return. The plans for “reduced operations,” once finalized, could provide some clarity to US diplomats and their families who have been displaced.Meanwhile, efforts to bring the war to an end have faltered. The memorandum of understanding between the two sides has collapsed. There was more than a week of back-and-forth strikes at the end of July. A renewed push for an agreement to fully reopen the Strait of Hormuz has yet to succeed.The State Department did not reduce staffing at most of its embassies in the region before the US and Israel began their military campaign. Ahead of the war, only Lebanon and Israel were in ordered and authorized departure status, respectively. Authorized departure means nonemergency personnel and family members could choose to leave but were not required to.Within weeks, as US diplomatic facilities across the region came under attack by Iran and its proxies, the department ordered nonemergency personnel and families to leave Bahrain, Iraq, Jordan, Qatar, Saudi Arabia and the United Arab Emirates. The US Embassy in Kuwait suspended operations entirely in March and only resumed emergency operations for Americans in late June. It remains under ordered departure. The US Embassy in Oman is under authorized departure.The sudden drawdown in staffing left diplomats and family members, many of whom had years left on their assignments, scrambling to find housing and to enroll their children in school back in the US. However, because it was unclear how long embassies would operate with reduced staffing, families couldn’t make longer-term commitments when they returned home. If normal operations resumed, they would be expected to quickly return to the Middle East.One diplomatic spouse said their family has been “hopping around to different housing situations this whole time,” because they couldn’t risk the potential financial repercussions of signing a long-term lease and breaking it.“We’ve had evacuations in various parts of the world, but this is different in that there’s such a large portion of people from one part of the world with so many people coming back to one spot,” they added.Those who were forced to leave the region left behind almost all of their belongings, as well as support networks of friends who can be critical to an overseas posting.The diplomatic spouse told CNN they feel “a tremendous sadness” for “the people we care about and the work that we’re part of” in the region.“We had no idea when we walked out of our house in March that we not only wouldn’t be returning in six months, but now the reality is, we won’t be returning at all,” they said, requesting anonymity due to concerns of retaliation.Under State Department rules, diplomatic posts cannot have their “ordered departure” status extended for more than 180 days. Once that limit is reached, if they are unable to return to normal status, they switch to “restricted operations,” which includes caps on in-country staffing. The State Department’s foreign affairs manual notes that restricted status “is intended as a temporary measure to address safety and security,” but “it may continue as long as necessary to ensure that adequate safety and security measures are in place.”For the posts in the Middle East, restricted operations status will likely mean no children and few spouses will be allowed to return, sources said.The State Department spokesperson said the department remains “committed to supporting our workforce and their families throughout this process and will provide updates through appropriate channels as decisions are made.”It will also mean a continued shortage of US diplomats on the ground. For those who are still not able to return to their posts, they may try to curtail, but it is not clear whether there are enough alternate jobs for them.And fewer diplomats on the ground could impact the State Department’s ability to provide quick consular assistance to Americans abroad and to advance the administration’s priorities, former diplomats said.“When you have fewer people, there’s less you can do, and there’s a lot that you cannot do remotely,” said John Bass, a former career diplomat who served as an under secretary of state for management.“The fewer diplomats you have in country, the fewer people you have who are focused on what is happening in that country, in that government, keeping tabs on key issues for the United States,” he explained. “You’ve got fewer people there to be promoting the US government’s views on what is happening and why, and what is in our interests and the interests of that country, working together, to try to solve a common problem.”He noted that leaders might discuss a broad agreement on a matter, but it comes down to the experienced diplomats on the ground “to be able to really get into the details with that host government about how to move forward.”Bass, who was an ambassador to Turkey, Georgia and Afghanistan, told CNN that the restricted operations status could potentially last “for months, if not years.”The State Department spokesperson disputed the idea that diplomatic efforts by the US have been “limited” by having fewer people on the ground.“We have seen sustained engagement from the highest levels of the Trump Administration with our partners in the Middle East, and our relationship with our allies in the region continues to get stronger,” they said.The-CNN-Wire™ & © 2026 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.
Read Next Story